Publisher's Synopsis
In the exciting and rapidly expanding field of drug development, there is an emphasis on the clear delineation of psychiatric symptoms, syndromes and disorders, and disorders, and improved strategies for making diagnoses. Here the authors concentrate on the anxiolytics, a group of drugs which must be evaluated in carefully defined groups of patients using sensitive outcome measures. Efficacy is not always easy to establish and large clinical trials are needed to verify effectiveness of the drug, the degree of efficacy and the risks of unwanted effects. Conducting these trials is not an easy matter and this timely, critical and comprehensive guide aims to provide awareness of the major issues surrounding development of anxiolytics and, in particular, details of the techniques needed to assess new and hopefully improved therapies. This book, written by authors well known for their extensive experience in the field of drug development, will be of interest to the academic community frequently involved in clinical trials of potential anxiolytic compounds, as well as to the pharmaceutical industry in the formulation of drug development programmes for new anxiolytics.
